Bausch Health Companies Inc.
BHCBausch Health Companies Inc. (formerly Valeant and ICN Pharmaceuticals) is a global, diversified Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic pharmaceuticals, and over-the-counter products directly or indirectly in more than 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific and Latin America.
Drugs in Pipeline
52
Phase 3 Programs
33
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How BHC's past catalysts played out
5 ASA, enemas, suppositories, corticosteroids
Ulcerative Colitis
IDP 121 Lotion
Acne
Rifaximin
Irritable Bowel Syndrome
Rifaximin SSD
Hepatic Encephalopathy
Omeprazole sodium bicarbonate immediate release PWD/FS
Upper Gastrointestinal Bleeding
crofelemer
Irritable Bowel Syndrome
IDP-123 Lotion
Acne Vulgaris
210 mg brodalumab
Psoriatic Arthritis
Balsalazide disodium
Inflammatory Bowel Disease
IDP-122 Lotion
Plaque Psoriasis
IDP-120 Gel
Acne Vulgaris
Neuromultivit
Vertebrogenic Radiculopathy L5, S1
IDP-122 Vehicle Lotion
Psoriasis
Crofelemer 125 mg
HIV Associated Diarrhea
IDP-120 Vehicle Gel
Acne Vulgaris
IDP-118 Vehicle Lotion
Plaque Psoriasis
Encapsulated Mesalamine Granules (eMG)
Ulcerative Colitis
MOA-728
Constipation
IDP-126 Vehicle Gel
Acne Vulgaris
IDP-123 Vehicle Lotion
Acne Vulgaris
Granulated mesalamine
Ulcerative Colitis
Larsucosterol
Hepatitis
Bisacodyl
Chronic Idiopathic Constipation
IDP-121 Lotion
Acne
open-label rifaximin
Irritable Bowel Syndrome With Diarrhea
Plecanatide
Chronic Idiopathic Constipation
Viramidine
Chronic Hepatitis C
ACYC
Acne
IDP-126 Gel
Acne Vulgaris
IDP-118 Lotion
Plaque Psoriasis
IDP-124 Lotion
Atopic Dermatitis
IDP-124 Vehicle Lotion
Atopic Dermatitis
Rifaximin (Xifaxan)
Clostridium Infections
SP-333 1 mg
Constipation
IDP-118 Vehicle Cream
Psoriasis
Low Dose MT-1303
Ulcerative Colitis
Mesalamine Granules 750 mg
Irritable Bowel Syndrome With Diarrhea
SP-304 0.3 mg
Chronic Idiopathic Constipation
SC MNTX
Bowel Dysfunction
pradefovir mesylate
Hepatitis B, Chronic
Low Dose Rifaximin ER
Sickle Cell Disease
Tazorac Cream
Psoriasis
IDP-126 Component A
Acne Vulgaris
40 mg Rifaximin SSD once daily
Overt Hepatic Encephalopathy
Rifaximin SSD 40 mg IR tablet
Liver Cirrhosis
Retigabine
Postherpetic Neuralgia
IDP-118 Monad HP Lotion
Plaque Psoriasis
SAN-300 0.5 mg/kg QW
Rheumatoid Arthritis
70 mg SC
Psoriasis
1.2% JNJ 10229570-AAA
Acne Vulgaris
IDP 120 Component A Gel
Acne Vulgaris
Retin-A Micro 0.04% facial acne treatment
Acne Vulgaris
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
5 ASA, enemas, suppositories, corticosteroids | Phase 3 | Ulcerative Colitis | - | - |
IDP 121 Lotion | Phase 3 | Acne | - | - |
Rifaximin | Phase 3 | Irritable Bowel Syndrome | - | - |
Rifaximin SSD | Phase 3 | Hepatic Encephalopathy | - | - |
Omeprazole sodium bicarbonate immediate release PWD/FS | Phase 3 | Upper Gastrointestinal Bleeding | - | - |
crofelemer | Phase 3 | Irritable Bowel Syndrome | - | - |
IDP-123 Lotion | Phase 3 | Acne Vulgaris | - | - |
210 mg brodalumab | Phase 3 | Psoriatic Arthritis | - | - |
Balsalazide disodium | Phase 3 | Inflammatory Bowel Disease | - | - |
IDP-122 Lotion | Phase 3 | Plaque Psoriasis | - | - |
IDP-120 Gel | Phase 3 | Acne Vulgaris | - | - |
Neuromultivit | Phase 3 | Vertebrogenic Radiculopathy L5, S1 | - | - |
IDP-122 Vehicle Lotion | Phase 3 | Psoriasis | - | - |
Crofelemer 125 mg | Phase 3 | HIV Associated Diarrhea | - | - |
IDP-120 Vehicle Gel | Phase 3 | Acne Vulgaris | - | - |
IDP-118 Vehicle Lotion | Phase 3 | Plaque Psoriasis | - | - |
Encapsulated Mesalamine Granules (eMG) | Phase 3 | Ulcerative Colitis | - | - |
MOA-728 | Phase 3 | Constipation | - | - |
IDP-126 Vehicle Gel | Phase 3 | Acne Vulgaris | - | - |
IDP-123 Vehicle Lotion | Phase 3 | Acne Vulgaris | - | - |
Granulated mesalamine | Phase 3 | Ulcerative Colitis | - | - |
Larsucosterol | Phase 3 | Hepatitis | - | - |
Bisacodyl | Phase 3 | Chronic Idiopathic Constipation | - | - |
IDP-121 Lotion | Phase 3 | Acne | - | - |
open-label rifaximin | Phase 3 | Irritable Bowel Syndrome With Diarrhea | - | - |
Plecanatide | Phase 3 | Chronic Idiopathic Constipation | - | - |
Viramidine | Phase 3 | Chronic Hepatitis C | - | - |
ACYC | Phase 3 | Acne | - | - |
IDP-126 Gel | Phase 3 | Acne Vulgaris | - | - |
IDP-118 Lotion | Phase 3 | Plaque Psoriasis | - | - |
IDP-124 Lotion | Phase 3 | Atopic Dermatitis | - | - |
IDP-124 Vehicle Lotion | Phase 3 | Atopic Dermatitis | - | - |
Rifaximin (Xifaxan) | Phase 3 | Clostridium Infections | - | - |
SP-333 1 mg | Phase 2 | Constipation | - | - |
IDP-118 Vehicle Cream | Phase 2 | Psoriasis | - | - |
Low Dose MT-1303 | Phase 2 | Ulcerative Colitis | - | - |
Mesalamine Granules 750 mg | Phase 2 | Irritable Bowel Syndrome With Diarrhea | - | - |
SP-304 0.3 mg | Phase 2 | Chronic Idiopathic Constipation | - | - |
SC MNTX | Phase 2 | Bowel Dysfunction | - | - |
pradefovir mesylate | Phase 2 | Hepatitis B, Chronic | - | - |
Low Dose Rifaximin ER | Phase 2 | Sickle Cell Disease | - | - |
Tazorac Cream | Phase 2 | Psoriasis | - | - |
IDP-126 Component A | Phase 2 | Acne Vulgaris | - | - |
40 mg Rifaximin SSD once daily | Phase 2 | Overt Hepatic Encephalopathy | - | - |
Rifaximin SSD 40 mg IR tablet | Phase 2 | Liver Cirrhosis | - | - |
Retigabine | Phase 2 | Postherpetic Neuralgia | - | - |
IDP-118 Monad HP Lotion | Phase 2 | Plaque Psoriasis | - | - |
SAN-300 0.5 mg/kg QW | Phase 2 | Rheumatoid Arthritis | - | - |
70 mg SC | Phase 2 | Psoriasis | - | - |
1.2% JNJ 10229570-AAA | Phase 2 | Acne Vulgaris | - | - |
IDP 120 Component A Gel | Phase 2 | Acne Vulgaris | - | - |
Retin-A Micro 0.04% facial acne treatment | Phase 2 | Acne Vulgaris | - | - |
Frequently asked questions
What is in Bausch Health Companies Inc.'s drug pipeline?→
CatalystAlert tracks 52 drug candidates in Bausch Health Companies Inc.'s (BHC) pipeline across Phase 3, Phase 2. Its lead program is 5 ASA, enemas, suppositories, corticosteroids (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bausch Health Companies Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Bausch Health Companies Inc. (BHC) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BHC biotech catalysts?→
Add BHC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bausch Health Companies Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.